Japan’s Ministry of Health, Labour and Welfare (MHLW) has set the initial reimbursement price for Eisai Co., Ltd./Biogen, Inc.’s Alzheimer's drug Leqembi (lecanemab) under the national health insurance (NHI) scheme, paving the way for a market launch in the country on 20 December.
The intravenously administered, amyloid beta-targeting antibody, approved for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease on 25 September, will be reimbursed at JPY45,777...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?